Compare Neurocrine Biosciences Inc (NBIX) vs Consumer Discretionary Select Sector SPDR Fund (XLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Consumer Discretionary Select Sector SPDR Fund — how do they compare? Neurocrine Biosciences Inc trades at $142.2 (market cap $14.36B), while Consumer Discretionary Select Sector SPDR Fund trades at $112.94 (market cap $21.89B). The key difference: Consumer Discretionary Select Sector SPDR Fund is the larger of the two by market cap, and Consumer Discretionary Select Sector SPDR Fund is more actively traded (5,690,342 versus 1,237,180). Which is the better fit depends on your goals — on Pluang, investors hold Neurocrine Biosciences Inc for 23 Days and Consumer Discretionary Select Sector SPDR Fund for 114 Days on average.
| NBIX | XLY | |
|---|---|---|
Market Cap | $14.36B | $21.89B |
Volume | 1,237,180 | 5,690,342 |
Sector | Health | — |
52-Week High | $185.50 | $124.52 |
52-Week Low | $123.10 | $105.64 |
Typical Hold Time | 23 Days | 114 Days |
Enterprise Value | $14.37B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $142.84, down 0.44% today, with strong fundamental performance including three consecutive quarterly earnings beats and robust profitability metrics. The stock shows bearish technical signals with resistance at $142-145, while maintaining excellent analyst support with 86% buy ratings and a $204 consensus target. Recent developments include pipeline advancements in Prader-Willi syndrome and executive appointments.
NBIX presents a compelling growth story with 20.9% net margins and expanding rare-disease portfolio, though faces execution risks as it diversifies beyond Ingrezza. The 43% upside to consensus target suggests significant potential, but investors must monitor pricing pressures and pipeline execution amid elevated valuation multiples.
XLY trades at $112.72, up 1.22% today, with a bullish technical signal despite mixed moving average and oscillator readings. The ETF shows strong analyst support with a 100% buy rating from coverage, though recent underperformance versus consumer staples highlights sector rotation pressures. Key technical levels show support at $110-$111 and resistance at $112-$113, with RSI indicating potential overbought conditions on shorter timeframes.
Outlook remains cautiously optimistic given analyst consensus, but investors face headwinds from inflation pressures on discretionary spending and ongoing underperformance versus broader market. The 'funflation' trend supporting consumer leisure spending provides potential upside, though valuation metrics remain unavailable for comprehensive assessment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Consumer Discretionary Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: retail; hotels, restaurants and leisure; textiles, apparel and luxury goods; household durables; automobiles; auto components; distributors; leisure products; and diversified consumer services. It is non-diversified.
Read more on XLY →
